Evidence map›Paper›PMID 31342191›Full record

ReviewCurrent pain and headache reports2019

Advances in the Understanding and Management of Chronic Pain in Multiple Sclerosis: a Comprehensive Review.

Ivan Urits, Leena Adamian, Jacob Fiocchi, Dylan Hoyt, Carly Ernst, Alan D Kaye, Omar Viswanath

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Dysregulation of sphingolipid metabolism in pain.Frontiers in pharmacology · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Ivan UritsBeth Israel Deaconess Medical Center, Department of Anesthesia, Critical Care, and Pain Medicine, Harvard Medical School, 330 Brookline Ave, Boston, MA, 02215, USA. iurits@bidmc.harvard.edu.
Leena AdamianCreighton University School of Medicine, Phoenix Regional Campus, Phoenix, AZ, USA.
Jacob FiocchiCreighton University School of Medicine, Phoenix Regional Campus, Phoenix, AZ, USA.
Dylan HoytCreighton University School of Medicine, Phoenix Regional Campus, Phoenix, AZ, USA.
Carly ErnstA T Still University, Kirksville College Of Osteopathic Medicine, Kirksville, MO, USA.
Alan D KayeDepartment of Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Omar ViswanathValley Anesthesiology and Pain Consultants, Phoenix, AZ, USA.
Creighton University · USA.T. Still University · USHarvard University · USLouisiana State University Health Sciences Center New Orleans · USPhoenix (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewMultiple sclerosis (MS) is an autoimmune disorder of the central nervous system that can lead to severe physical, cognitive, and neurological deficits that often manifest in young adults. Central neuropathic pain is a common presenting symptom, often prompting patients to seek treatment with opioids, NSAIDS, antiepileptics, and antidepressants despite minimal effectiveness and alarming side-effect profiles. Additionally, spasticity occurs in more than 80% of MS patients and is an important consideration for further study in treatment. RECENT

findingsRelated to inconsistencies in pain presentation and clinical reporting, current studies continue to investigate clinical patient presentation to define chronic pain characteristics to optimize treatment plans. Although often neuropathic in origin, the complex nature of such pain necessitates a multimodal approach for adequate treatment. While psychiatric comorbidities typically remain unchanged in their severity over time, physical conditions may lead to worsening chronic pain long-term, often due to decreased quality of life. The prevalence of neuropathic pain is ~ 86% in patients with multiple sclerosis and most commonly presents as extremity pain, trigeminal neuralgia, back pain, or headaches. As MS symptoms are frequently unremitting and poorly responsive to conventional medical management, recent attention has been given to novel interventions for management of pain. Among these, medicinal cannabis therapy, targeted physical therapy, and neuromodulation offer promising results. In this review, we provide a comprehensive update of the current perspective of MS pathophysiology, symptomatology, and treatment.

Indexed as

Chronic PainHumansMultiple SclerosisNeuralgiaPain ManagementChronic painCnsMsMultiple sclerosisNeuropathic pain

Identifiers

PMID31342191
OpenAlexW2963907221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.